Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy

BMC Medical Research Methodology

Volumn 8, Issue , 2008, Pages

  Wittkop, Linda ^a,b   Commenges, Daniel ^a,b   Pellegrin, Isabelle ^c   Breilh, Dominique ^c   Neau, Didier ^c   Lacoste, Denis ^c   Pellegrin, Jean Luc ^c   Chêne, Geneviève ^a,b   Dabis, François ^a,b   Thiébaut, Rodolphe ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; VIRUS MUTATION; BLOOD; DRUG EFFECT; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS; METHODOLOGY; MUTATION; PRINCIPAL COMPONENT ANALYSIS; REGRESSION ANALYSIS;

ANTI-HIV AGENTS; GENOTYPE; HIV; HUMANS; LEAST-SQUARES ANALYSIS; MUTATION; PRINCIPAL COMPONENT ANALYSIS; RNA, VIRAL;

EID: 58149094045     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-8-68     Document Type: Article

References (22)

1. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). B Gazzard AJ Bernard M Boffito D Churchill S Edwards N Fisher AM Geretti M Johnson C Leen B Peters, HIV Med 2006 7 487 503 10.1111/j.1468-1293.2006.00424.x 17105508
2. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. SM Hammer MS Saag M Schechter JS Montaner RT Schooley DM Jacobsen MA Thompson CC Carpenter MA Fischl BG Gazzard, Jama 2006 296 827 843 10.1001/jama.296.7.827 16905788
3. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. MS Hirsch F Brun-Vezinet B Clotet B Conway DR Kuritzkes RT D'Aquila LM Demeter SM Hammer VA Johnson C Loveday, Clin Infect Dis 2003 37 113 128 10.1086/375597 12830416
4. Report 2006 under the direction of Patrick Yeni: Prise en charge médicale des personnes infectées par le VIH, recommandations du groupe d'experts. République française, Médecines-Sciences, Flammarion 2006 http://www.sante.gouv.fr/htm/actu/yeni_sida/ rapport_experts_2006.pdf (accessed 29 october 2008)
5. Clinically validated genotype analysis: guiding principles and statistical concerns. F Brun-Vezinet D Costagliola MA Khaled V Calvez F Clavel B Clotet R Haubrich D Kempf M King D Kuritzkes, Antivir Ther 2004 9 465 478 15456077
6. Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study. P Flandre AG Marcelin J Pavie N Shmidely M Wirden O Lada MC Bernard JM Molina V Calvez, Antivir Ther 2005 10 479 487 16038473
7. Using principal components for estimating logistic regression with high-dimensional multicollinear data. A Aguilera M Escabias M Valderrama, Comput Stat Data Anal 2006 50 1905 1924 10.1016/j.csda.2005.03.011
8. PLS generalised linear regression. P Bastien V Esposito Vinzi M Tenenhaus, Comput Stat Data Anal 2005 48 17 46 10.1016/j.csda.2004.02.005
9. Principal Components Regression in Exploratory Statistical Research. W Massy, Journal of the American Statistical Association 1965 60 234 256 10.2307/2283149
10. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. I Pellegrin D Breilh G Coureau S Boucher D Neau P Merel D Lacoste H Fleury MC Saux JL Pellegrin, Antimicrob Agents Chemother 2007 51 1473 1480 17296739 10.1128/AAC.00481-06
11. Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients. A-G Marcelin B Masquelier D Descamps J Izopet C Charpentier C Alloui M Bouvier-Alias A Signori-Schmuck B Montes M-L Chaix, Antimicrob Agents Chemother 2008 52 3237 3243 10.1128/AAC.00133-08 18625773
12. PLS regression, PLS path modeling and generalized Procrustean analysis: a combined approach for multiblock analysis. M Tenenhaus V Esposito Vinzi, Journal of Chemometrics 2005 19 145 153 10.1002/cem.917
13. The PLS Procedure. SAS, Institute, Inc, SAS Online Doc SAS Online Doc. 9.1.3: SAS Institute Inc., Cary, NC, USA 2007 913 http://support.sas.com/ onlinedoc/913/docMainpage.jsp accessed 29 october 2008
14. Update of the Drug Resistance Mutations in HIV-1: 2007. VA Johnson F Brun-Vezinet B Clotet HF Gunthard DR Kuritzkes D Pillay JM Schapiro DD Richman, Top HIV Med 2007 15 119 125 17720996
15. HIV-1 subtype B protease and reverse transcriptase amino acid covariation. SY Rhee TF Liu SP Holmes RW Shafer, PLoS Comput Biol 2007 3 e87 17500586 10.1371/journal.pcbi.0030087
16. Accurate prediction of HIV-1 drug response from the reverse transcriptase and protease amino acid sequences using sparse models created by convex optimization. M Rabinowitz L Myers M Banjevic A Chan J Sweetkind-Singer J Haberer K McCann R Wolkowicz, Bioinformatics 2006 22 541 549 10.1093/bioinformatics/btk011 16368772
17. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. C Garriga MJ Perez-Elias R Delgado L Ruiz R Najera T Pumarola M Alonso-Socas Mdel S Garcia-Bujalance L Menendez-Arias, J Med Virol 2007 79 1617 1628 10.1002/jmv.20986 17854027
18. Covariation of amino acid positions in HIV-1 protease. NG Hoffman CA Schiffer R Swanstrom, Virology 2003 314 536 548 10.1016/S0042-6822(03)00484-7 14554082
19. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. TD Wu CA Schiffer MJ Gonzales J Taylor R Kantor S Chou D Israelski AR Zolopa WJ Fessel RW Shafer, J Virol 2003 77 4836 4847 12663790 10.1128/JVI.77.8.4836-4847.2003
20. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. M Maguire D Shortino A Klein W Harris V Manohitharajah M Tisdale R Elston J Yeo S Randall F Xu, Antimicrob Agents Chemother 2002 46 731 738 11850255 10.1128/AAC.46.3.731-738.2002
21. Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment. RM Kagan PK Cheung TK Huard MA Lewinski, Antiviral Res 2006 71 42 52 10.1016/j.antiviral.2006.02.008 16600392
22. Update of the drug resistance mutations in HIV-1: 2004. VA Johnson F Brun-Vezinet B Clotet B Conway RT D'Aquila LM Demeter DR Kuritzkes D Pillay JM Schapiro A Telenti DD Richman, Top HIV Med 2004 12 119 124 15516709